Ppembrolizumab· Business · 6 sources · Sep 3, 2026StoryCipla and Qilu ink exclusive deal to sell Keytruda biosimilar in USInvagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.Business· Sep 3, 2026+3+23ShareDerek Foss·Sep 4, 2026Top commentPatent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.00ReplyGenius replyShareWrite a comment…
Ppembrolizumab· Health · 543 sources · Aug 19, 2026StoryMelanoma Trial Shows Positive Personalized mRNA VaccineMerck and Moderna reported positive Phase 3 results for their personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) added to Keytruda in high-risk, surgically treated melanoma, showing longer recurrence-free survival and reduced distant metastasis with no new safety issues. The companies plan regulatory discussions and potential accelerated approval submissions, with data presentations at upcoming medical meetings and continued follow-up for overall survival.Health· Aug 19, 2026+5400CommentShareWrite a comment…
